Enfortumab Vedotin

證據等級: L5

預測適應症: 9 個

Enfortumab Vedotin: From Urothelial (Bladder) Cancer to Leprosy

One-Sentence Summary

Enfortumab vedotin is an antibody-drug conjugate (ADC) whose established clinical use context in this evidence pack is advanced/metastatic bladder (urothelial) cancer. The TxGNN model's top-ranked prediction for this drug is Leprosy, with a raw score of 99.53%, but zero clinical trials and zero publications currently support this specific drug–disease pairing, and the model's own mechanistic rationale explicitly finds no plausible biological link.

Quick Overview

Item	Content
Original Indication	Not present in structured `original_indications`/regulatory license data (data gap). Contextual literature evidence in this pack (PMID 41341429) identifies enfortumab vedotin as an ADC used in advanced bladder cancer patients — this is the only indication context available.
Predicted New Indication	Leprosy
TxGNN Prediction Score	99.53% (raw score 0.9953; global candidate rank 5,642)
Evidence Level	L5 — model prediction only, no supporting clinical trials or literature
Germany Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, the structured mechanism-of-action field for enfortumab vedotin is a documented data gap (DG002, High severity). However, the model's own repurposing-rationale text consistently and independently describes the drug across multiple candidate entries as an anti-Nectin-4 antibody-drug conjugate (ADC): an antibody targeting the Nectin-4 tumor surface antigen delivers a microtubule-disrupting cytotoxin (MMAE, monomethyl auristatin E) into antigen-expressing cells, producing direct cytotoxicity.

Leprosy, by contrast, is an infectious disease caused by Mycobacterium leprae, treated through antimycobacterial chemotherapy (e.g., multidrug therapy with dapsone, rifampicin, clofazimine) rather than targeted cytotoxic delivery. There is no known Nectin-4 involvement in M. leprae pathophysiology, and no receptor- or pathway-level overlap between an antimycobacterial mechanism and a tumor-antigen-directed cytotoxic payload.

This is stated directly in the evidence pack's own repurposing rationale: "Enfortumab vedotin … shows no known association with antimycobacterial infection mechanisms, and no receptor/pathway overlap evidence exists." In other words, the source data itself concludes the mechanistic hypothesis is unsupported — this is a pure similarity-based model output (TxGNN rank 5,642, well outside typical high-confidence prediction territory) with no corroborating clinical, preclinical, or literature signal. This prediction should be treated as exploratory/noise-level rather than a genuine repurposing lead.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Enfortumab vedotin currently holds no marketing authorizations on record for this market (0 licenses; market status: Not Marketed). No authorization table can be produced.

Cytotoxicity

Enfortumab vedotin's underlying drug class (per repurposing-rationale text embedded in this evidence pack) is an antibody-drug conjugate delivering a microtubule-inhibitor payload, i.e., a cytotoxic anticancer agent, so this section is included.

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (anti-Nectin-4 antibody + MMAE microtubule inhibitor payload)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

(Detailed toxicity/warning data could not be retrieved — this is a documented Blocking data gap, DG001: TFDA/package-insert warnings and contraindications, required before any Stage 1 safety screening.)

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

The prediction carries no clinical, preclinical, or literature support (0 trials, 0 publications), sits at evidence level L5, and the model's own mechanistic rationale explicitly states there is no known biological link between an anti-Nectin-4 ADC's cytotoxic mechanism and leprosy's infectious/antimycobacterial treatment paradigm. There is no basis to advance this candidate past initial screening.

To proceed, the following is needed:

Formal DrugBank/regulatory mechanism-of-action (MOA) data (DG002)
TFDA/package-insert warnings, contraindications, and drug-interaction data (DG001, Blocking — required before any safety evaluation can begin, for this drug in general, regardless of indication)
Independent biological rationale (e.g., Nectin-4 expression or relevant target expression in leprosy-affected tissue, or any published case reports) before this pairing is worth further investment
Given the complete absence of supporting evidence, this candidate is not recommended for further evaluation resources at this time

Appendix: Other Model-Predicted Indications Reviewed (Ranks 2–9)

For completeness, the remaining top-9 TxGNN predictions in this evidence pack were also reviewed and show the same pattern — no supporting trials, and mechanistic rationales that consistently argue against biological plausibility:

Rank	Predicted Disease	Score	Note
2	Multiple endocrine neoplasia	99.43%	Genetic (MEN1/RET) endocrine tumor syndrome; no evidence of Nectin-4 expression relevance
3	Cytomegalovirus infection	99.36%	Viral infection; cytotoxic ADC mechanism has no antiviral rationale and could theoretically worsen infection risk via myelosuppression
4	Candidiasis	99.30%	Sole literature hit (PMID 41341429) is a FAERS pharmacovigilance signal describing candidiasis as an adverse event in ADC-treated bladder cancer patients — i.e., evidence of harm, not efficacy; this should not be read as supportive
5	Cerebral infarction	99.23%	Ischemic vascular disease; no mechanistic overlap, and ADC-related toxicities (myelosuppression, neuropathy) run counter to this indication
6	HIV infectious disease	99.19%	Antiretroviral mechanism unrelated to ADC cytotoxicity
7	Homozygous familial hypercholesterolemia	99.18%	Lipid-metabolism/LDL-receptor disorder; no pharmacologic overlap
8	Malignant catarrh (malignant catarrhal fever)	99.13%	Veterinary disease (bovine/ruminant herpesvirus) — likely a cross-species ontology mapping artifact, not a valid human indication
9	Infectious bovine rhinotracheitis	99.13%	Veterinary disease (bovine herpesvirus-1) — same likely ontology artifact as rank 8

Recommendation: None of the top-9 candidates in this batch meet even preliminary plausibility thresholds. Ranks 8–9 in particular suggest a data-quality/ontology-mapping issue (veterinary vs. human disease terms) that may warrant a knowledge-graph data-cleaning review rather than clinical follow-up.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.